Astegolimab, an anti-ST2, in COPD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial
Lancet Respir Med 2022 May 01;10(5)469-477, AJ Yousuf, S Mohammed, L Carr, M Yavari Ramsheh, C Micieli, V Mistry, K Haldar, A Wright, P Novotny, S Parker, S Glover, J Finch, N Quann, CL Brookes, R Hobson, W Ibrahim, RJ Russell, C John, MA Grimbaldeston, DF Choy, D Cheung, M Steiner, NJ Greening, CE BrightlingFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.